The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Quality of life after tildrakizumab treatment for plaque psoriasis: Results from a phase IV study
|
Tildrakizumab, an anti-IL-23 mAb, is approved for the treatment of moderate-to-severe plaque psoriasis in adult patients.1 A phase IV real-world, open-label, US-based study (NCT03718299) was initiated to evaluate the effect of tildrakizumab on HRQoL in patients with plaque psoriasis. A total of 55 patients were enrolled; 45 patients completed 64 weeks of treatment and were subsequently assessed. The primary endpoint was improvement in PGWBI from baseline. Changes to DLQI and safety outcomes were also assessed.1
|
| Key learnings |
|
Significant improvements were observed in PGWBI and DLQI. The mean PGWBI score improved over time, increasing from 78.1 at baseline to 85.2 at Week 52 (p < 0.001). Mean DLQI score improved from 9.4 to 2.0 by Week 64 (p < 0.001). |
|
Significant improvements were seen in the PGWBI subdomains of positive well-being and general health. Other domains, such as anxiety and depression, showed improvement trends. |
|
At Week 64, 62.2% of patients reported minimal or no impact of psoriasis on their QoL (DLQI 0/1). These improvements were evident from Week 4, indicating rapid and sustained benefits, with the proportion of patients achieving DLQI 0/1 increasing over time. |
|
Overall, tildrakizumab demonstrated long-term effectiveness in enhancing both psychological and skin-related QoL, with no adverse events reported relating to tildrakizumab treatment. This real-world evidence strengthens confidence in tildrakizumab as a treatment for improving patient-reported outcomes. |
Abbreviations: DLQI, Dermatology Life Quality Index; HRQoL, health-related quality of life; IL, interleukin; mAb, monoclonal antibody; PGWBI, Psychological General Well-Being Index; QoL, quality of life.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
